ADAP's logo.
Ticker Symbol: ADAP

Adaptimmune Therapeutics Plc - ADR

$4.33 - 01-11-2024 4 p.m. ET

Exchange: NASDAQ Country: United Kingdom Currency: USD Asset Type: ADR CIK:0001621227

Company Profile

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: 60 Jubilee Avenue
CEO: N/A
Tags:
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing

Pricing

Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $0.56
Change: -$0.01 ( -2.59%)
Days Range: $0.55 - $0.60
Beta: 1.01
52wk. High: $2.65
52wk. Low: $0.56
Ytd. Change -63.89%
50 Day Moving Average: $0.73
200 Day Moving Average: $0.98
Shares Outstanding: 154661381

Valuation

Market Cap: 8.7B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A